$10.80
2.70% yesterday
Nasdaq, Oct 06, 10:00 pm CET
ISIN
US24661P5008
Symbol
DCTH

Delcath Systems Inc Stock price

$10.80
-0.75 6.49% 1M
-0.11 1.01% 6M
-1.24 10.30% YTD
+2.28 26.76% 1Y
+7.66 243.95% 3Y
-0.37 3.31% 5Y
-940,799,989.20 100.00% 10Y
-90,003,199,989.20 100.00% 20Y
Nasdaq, Closing price Mon, Oct 06 2025
-0.30 2.70%

Key metrics

Basic
Market capitalization
$388.3m
Enterprise Value
$307.3m
Net debt
positive
Cash
$81.0m
Shares outstanding
35.0m
Valuation (TTM | estimate)
P/E
222.0 | 230.9
P/S
5.5 | 4.0
EV/Sales
4.4 | 3.2
EV/FCF
79.4
P/B
3.7
Financial Health
Equity Ratio
89.8%
Return on Equity
-38.4%
ROCE
4.7%
ROIC
12.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$70.2m | $96.4m
EBITDA
$5.2m | $24.3m
EBIT
$5.0m | $293.8k
Net Income
$2.2m | $1.7m
Free Cash Flow
$3.9m
Growth (TTM | estimate)
Revenue
491.7% | 159.2%
EBITDA
114.4% | 297.7%
EBIT
113.9% | 102.4%
Net Income
104.0% | 106.4%
Free Cash Flow
112.3%
Margin (TTM | estimate)
Gross
85.9%
EBITDA
7.4% | 25.2%
EBIT
7.1%
Net
3.2% | 1.7%
Free Cash Flow
5.5%
More
EPS
$0.1
FCF per Share
$0.1
Short interest
9.3%
Employees
96
Rev per Employee
$390.0k
Show more

Is Delcath Systems Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Delcath Systems Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Delcath Systems Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Delcath Systems Inc forecast:

Buy
92%
Hold
8%

Financial data from Delcath Systems Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
70 70
492% 492%
100%
- Direct Costs 9.93 9.93
265% 265%
14%
60 60
559% 559%
86%
- Selling and Administrative Expenses 37 37
27% 27%
52%
- Research and Development Expense 19 19
13% 13%
27%
5.18 5.18
114% 114%
7%
- Depreciation and Amortization 0.17 0.17
31% 31%
0%
EBIT (Operating Income) EBIT 5.01 5.01
114% 114%
7%
Net Profit 2.23 2.23
104% 104%
3%

In millions USD.

Don't miss a Thing! We will send you all news about Delcath Systems Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Delcath Systems Inc Stock News

Neutral
Business Wire
14 days ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the acceptance of an oral presentation on results from the investigator-initiated CHOPIN randomized Phase 2 trial at the 2025 European Society for Medical Oncology (ESMO) Annual Congress. Principal Investiga...
Neutral
Business Wire
about one month ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to three individuals whose employment commenced in J...
Neutral
Business Wire
about 2 months ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences: Wells Fargo Healthcare Conference on Thursday, September 4, 2025, in Boston, MA H.C. Wainwright 27th Annual Global Investment Conf...
More Delcath Systems Inc News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.

Head office United States
CEO Gerard Michel
Employees 96
Founded 1988
Website delcath.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today